Carvedilol(CAS:72956-09-3)

Carvedilol, CAS 72956-09-3, is a third-generation composite adrenergic receptor blocker pharmaceutical API. With unique dual α/β blocking mechanism and antioxidant cardioprotective activity, it has become one of the most comprehensively advantageous raw materials for cardiovascular treatment. Widely used in the standardized therapy of hypertension, heart failure and myocardial injury, it is included in multiple international pharmacopoeias and serves as an essential raw material for high-end cardiovascular preparations. Featuring stable physical and chemical properties, mature synthesis technology and strict impurity control, Carvedilol meets global pharmaceutical standards and can be processed into oral tablets and sustained-release formulations, supporting large-scale industrial production and long-term chronic disease treatment.

In terms of pharmacological mechanism, Carvedilol has core advantages over traditional single beta blockers such as metoprolol. It comprehensively blocks α1, β1 and β2 adrenergic receptors to achieve bidirectional cardiovascular regulation. Blocking cardiac β1 receptors inhibits overactivated sympathetic nerves, reduces heart rate and myocardial oxygen consumption, relieves cardiac load, suppresses renin release and blocks RAAS activation to stabilize blood pressure fundamentally. Blocking vascular α1 receptors directly relaxes peripheral vascular smooth muscles, dilates blood vessels and reduces circulatory resistance, avoiding vasoconstriction and poor peripheral circulation caused by single beta inhibition. Moreover, Carvedilol has excellent antioxidant and anti-inflammatory properties, which eliminate oxygen free radicals, reduce myocardial oxidative damage, and inhibit myocardial fibrosis and vascular remodeling. It provides multi-target protection for the heart and blood vessels without interfering with human glucose and lipid metabolism, suitable for patients with cardiovascular diseases combined with metabolic disorders.

Clinically, Carvedilol covers a wide range of indications and is a first-line core API for chronic cardiovascular diseases. For hypertension treatment, it can be used alone or combined with diuretics and calcium channel blockers to achieve stable 24-hour blood pressure control, especially suitable for sympathetic excitatory hypertension and hypertensive patients complicated with heart failure and metabolic diseases. In the field of heart failure treatment, it is a cornerstone drug for chronic congestive heart failure, applicable to mild, moderate and severe conditions. Long-term medication reverses ventricular hypertrophy, improves left ventricular function, enhances patients’ exercise tolerance, and significantly reduces readmission and mortality rates. In addition, it is applied in the follow-up treatment of stable post-myocardial infarction patients to ameliorate left ventricular dysfunction and prevent deteriorated myocardial remodeling, as well as long-term management of stable angina to reduce ischemia attacks.

In terms of safety and industrial application, Carvedilol has excellent clinical tolerance with a wide therapeutic window. Adverse reactions under conventional doses are mild and controllable without obvious liver and kidney cumulative toxicity, enabling safe long-term medication for elderly and chronic disease patients. Its metabolic neutrality makes it the preferred API for cardiovascular patients with metabolic complications. At present, the mature domestic production process ensures stable batch quality, uniform purity and low impurities, meeting the mass production and export demands of global pharmaceutical enterprises. With the comprehensive advantages of dual-receptor blocking, multi-organ protection, wide adaptability and high safety, Carvedilol has gradually replaced traditional single blockers, maintaining stable market demand and broad development prospects in the field of chronic cardiovascular disease prevention and treatment worldwide.